approach to a patient with chest pain mpprc conference group 3 med 2c
DESCRIPTION
APPROACH TO A PATIENT WITH CHEST PAIN MPPRC CONFERENCE Group 3 MED 2C. GENERAL INFORMATION. Name: B.C. Age: 60 years old Gender: Male Citizenship: Filipino Religion: Roman Catholic Occupation: Farmer Address: Bulacan Source: Patient CHIEF COMPLAINT: CHEST PAIN. Chest pain - PowerPoint PPT PresentationTRANSCRIPT
1
APPROACH TO A PATIENTWITH
CHEST PAINMPPRC CONFERENCE
Group 3 MED 2C
2
GENERAL INFORMATION
Name: B.C.Age: 60 years oldGender: MaleCitizenship: Filipino Religion: Roman CatholicOccupation: FarmerAddress: BulacanSource: PatientCHIEF COMPLAINT: CHEST PAIN
3
2 years
1 month
Chest pain- grade 3/10- substernal- heaviness- effort related (3km walk)- relieved after 4 minutes of rest- recurs once a month
Chest pain- grade 6/10- 10- 20 meters walk- radiation to the left arm
Consult and admission
4
PAIN ASSESSMENT AND ALGORITHM
P - precipitating, aggravating, relief
Q - quality
R - radiation, location
S - severity (1-10)
T - timing
5
PAST MEDICAL HISTORY
• (+) Hypertension for 10 years– Highest BP 200/100 – Usual BP 140-150/90 – On irregular intake of metoprolol 50mg
• No previous surgical illness requiring hospitalization
6
FAMILY HISTORY
• Father: (+) HPN, (+) DM, sudden death at 55y/o
• Mother: (+) HPN, stroke at 60y/o
• Brother: (+) HPN, (+) DM
• Sister: (+) HPN, (+) DM
7
PERSONAL AND SOCIAL HISTORY
• Patient is a rice farmer in Bulacan• Fond of eating tuyo, bagoong, alamang• 50-pack year smoking history• Drinks 1-2 bottles of gin 3x a week• No illicit drug use
8
REVIEW OF SYSTEMS
• General Survey– No significant weight loss– No loss of consciousness and headache
• HEENT– No blurring of vision– No ear discharge or tinnitus
• Respiratory– No cough – No colds – No dyspnea
9
REVIEW OF SYSTEMS
• Gastro-intestinal– No epigastric pain – No diarrhea– No constipation – No melena– No hematochezia
• Genitourinary– No dysuria – No frequency – No urgency – No pollakiuria
10
REVIEW OF SYSTEMS
• Musculo-skeletal– No joint pains
• Endocrine/Metabolism– No polyuria – No polydypsia – No polyphagia– No heat or cold intolerance
11
PHYSICAL EXAMINATION
• General Survey– Conscious– Coherent – Normosthenic – Not in Cardiopulmonary distress
• Vital Signs– BP 160/90– PR 100/min regular– RR 19/min – T 37oc
12
PHYSICAL EXAMINATION
• Anthropometric Measurements– Height: 1.5 m– Weight: 52.6 kg– BMI: 23
• HEENT– Pink palpebral conjunctiva – Anicteric sclera – No nasal nor aural discharge – Moist buccal mucosa– No neck mass
13
PHYSICAL EXAMINATION• Respiratory
– Symmetrical chest expansion – No retraction – Resonant, unimpaired transmission of vocal and tactile fremiti– Clear breath sounds
• Gastrointestinal– Abdomen flabby – Normoactive bowel sounds – Tympanitic, nontender – Liver dullness 10cm – Traube’s space not obliterated
• Extremities– Pulses ++ on all extremities– No pedal edema
14MV
TV
PVAV
S1 S2 S1 S2
CAP
JVP 4.5cm at 45 deg
Adynamic precordium, apex beat 6th LICS AAL,
(-) heaves
15
CHIEF COMPLAINT:
Chest Pain“An unpleasant sensation in the anterior wall of the thorax associated with actual or potential tissue damage and mediated by specific nerve fiber to the brain where conscious appreciation may be modified by various factors. “
Stedmans Medical Dictionary, 27th edition
16
17
ORGAN SYSTEMS THAT COULD BE INVOLVED
Reference: Mosby’s Guide to Physical Examination, 6th edition
18
ORGAN SYSTEMS THAT COULD BE INVOLVED
Reference: Mosby’s Guide to Physical Examination, 6th edition
19
20
SALIENT FEATURES (SUBJECTIVE)Pertinent Positive (+)- 60 y/o male- Farmer- Chest pain- Hypertension- Preference for salty foods- 50 pack year smoking history- Alcohol drinkerFamily History- Hypertension- Diabetes mellitus- stroke
Pertinent Negative (-)- Fatigue- Dyspnea- Palpitations- Weight loss- Cough- Epigastric pain- Joint pain- Polyuria, polydypsia, polyphagia- Heat and cold intolerance
21
SALIENT FEATURES
Objective
- BP 160/90- Apex beat 6th LICS AAL
22
PATHOPHYSIOLOGY
23
24
MYOCARDIAL ISCHEMIA
• occurs when myocardial oxygen demand exceeds oxygen supply
25
PATHOGENESIS OF ATHEROSCLEROSIS
26
GeneticGeneticHyperlipidemiaHyperlipidemiaEndocrine (DM)Endocrine (DM)
Functional Impairment of EndotheliumFunctional Impairment of Endothelium
Increased LDL or other lipid influxIncreased LDL or other lipid influx
Initiation of InflammationInitiation of InflammationMonocyte InfluxMonocyte Influx
Initiation of InflammationInitiation of InflammationMonocyte InfluxMonocyte Influx
Inadequate Wound HealingSmooth muscle cell proliferation
Matrix DepositionAtheroma FormationThrombus Formation
Inadequate Wound HealingSmooth muscle cell proliferation
Matrix DepositionAtheroma FormationThrombus Formation
Occlusion of arteryOcclusion of artery
MECHANISM OF OCCLUSION
27
28Development of atherosclerotic plaque
29
MAJOR RISK FACTORS•Age: male > 45 y/o female > 55 y/o•Family history in a first degree relative of premature CAD (acute MI) male relative < 55 y/o female relative < 65 y/o•Diabetes mellitus•Chronic smoking•Hypertension•Obesity•Dyslipidemia
MINOR RISK FACTORS•Sedentary lifestyle•Chronic infection/ inflammation•hyperhomocysteinemia
Reference: ATP III
30
PATHOLOGY
31
Showing yellowish atherosclerotic plaques
GROSS SPECIMEN OF THE HEART
Image retrieved from: http://library.med.utah.edu/WebPath/CVHTML/CV005.html
32
HYPERTROPHIED HEART
Image retrieved: http://www.studentconsult.com/common/cfm
33
34
NORMAL CORONARY ARTERY
Image retrieved from: http://library.med.utah.edu/WebPath/CVHTML/CV005.html
35
Abn. >75% narrowing, assoc. w/ angina
Image retrieved from: http://library.med.utah.edu/WebPath/CVHTML/CV005.html
narrowing of the lumen due to build up of atherosclerotic plaque
CORONARY ARTERY WITH ATHEROSCLEROSIS
36
Normal myocardium Cardiac muscle w/ ischemia
Image retrieved: http://www.studentconsult.com/common/cfm and http://library.med.utah.edu/WebPath/TUTORIAL/MYOCARD/MI031.html
•central nuclei •syncytial arrangement of the fibers•pale pink intercalated disks
•myocytes hypertrophied•large, dark nuclei
37
PLAQUE STABILIZATIONUnstable plaque
Thinner vs thickerfibrous cap
Lipid core
•Greater lipid content and loose necrotic tissue create less echo on an ultrasound (hypoechogenicity), while dense fibrous tissue in more stable plaque creates more echo
(hyperechogenicity)
Stable plaque
More vs fewerinflammatory cells
Toschi V et al. Circulation. 1997;95:594-599; Libby P. Circulation. 1995;91:2844-2850; Schartl M et al. Circulation. 2001;104:387-392.
38
LV hypertrohy
Increase myocardial
oxygen demand
Necrosis
Hypoxia
Ischemia
CHEST PAINIncrease Lactic Acid
Increase anaerobic
respicration
39
REFERRED PAIN
40
41
• Stimulus PGE2, H+ ions, bradykinin, K+ ischemia• Primary viscerosensory fibers terminate in Lamina I
& V• Spinal segments also receive cutaneous
somatosensory input from dermatomes of the chest wall and arm
• Tract cells in the posterior horn that receive somatosensory input may also be activated
• Response Cerebral cortex interprets the pain as originating from the surface of the body
42
RADIOLOGIC AND ANCILLARY TESTS
43
DIAGNOSTIC TESTS
• Chest X ray• ECG• Ancillary test
- Lipid profile- fasting blood sugar
Reference: Harrison’s Principles of Internal Medicine 17 th Edition
44
X-RAYImportant in the diagnosis of the following:• cardiac enlargement• ventricular aneurysm• signs of heart failure
Important in assessing the degree of cardiac damage
Reference: Harrison’s Principles of Internal Medicine 17 th EditionReference: Harrison’s Principles of Internal Medicine 17 th Edition
45
X-RAY
46
NORMAL ECG ACTIVATIONNORMAL ECG ACTIVATION
47
S-T SEGMENT ELEVATIONS-T SEGMENT ELEVATION
48
S-T SEGMENT DEPRESSIONS-T SEGMENT DEPRESSION
49
T-WAVE INVERSIONT-WAVE INVERSION
50
ANCILLARY TESTS
• Lipid Profileo TC: < 200 mg/dLo LDL: < 130 mg/dLo HDL: > 60 mg/dL
• Fasting Blood Sugaro 70-99 mg/dL
Reference: Harrison’s Principles of Internal Medicine 17 th Edition
5151
PHARMACOLOGY
5252
TREATMENT GOALS
• Relieve symptoms of angina pectoris
– Correction of O2 delivery and demand imbalance for myocardial cells
– Increasing delivery– Decreasing O2 demand
• Treat any modifiable risk factors
5353
BASIC PHARMACOLOGY
• Four approved drug groups:
1. Organic Nitrates2. Ca2+ Channel Blockers3. ß-Blockers4. pFOX inhibitors
5454
NITROGLYCERINNO
cGMP
VASODILATION
GUANYLYL CYCLASE
NITRITES & NITRATES
• NITROGLYCERIN• MOA:
• Direct results:relaxation of veins preload, CO
• Indirect results: stimulation of guanylyl cyclase in platelets to platelet aggregation
• Increase myocardial O2 delivery
Reference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th editionReference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th edition
5555
Ca2+ CHANNEL BLOCKERS
• MOA:
– Inhibition of Ca2+ entry
– Ca2+ transmembrane current
– Vasodilation, vascular resistance
– myocardial contractile force
• Relieves and prevents focal coronary artery spasms
• LV wall stress declines
• cardiac contractility O2 requirement
Reference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th editionReference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th edition
5656
ß-BLOCKERS
• Management of angina with effort
• Not used for vasodilation
• O2 requirement
• MOA:
ß1 ANTAGONIST
HR, BPCONTRACTILITY
DIASTOLIC PERFUSION TIME
CORONARY PERFUSION
Reference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th editionReference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th edition
5757
OTHER ANTIANGINAL DRUGS
• pFOX inhibitors: partially inhibit FA oxidation pathway
• Shift myocardial metabolism toward use of glucose instead of FA
• O2 requirement
• RANOLAZINE
Reference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th edition.Reference: Bertram Katzung, MD. Basic and Clinical Pharmacology. 10th edition.
58
CLINICAL PHARMACOLOGYDRUG INDICATION NORMAL DOSE CONTRAINDICATIONS
Nitrates
Sublingual NTG Angina 0.3-0.6 mgintolerance of side effects: flushing, headache, ishchemia on withdrawal
Oral NTG Angina 2.5-5 mg q4-6h as aboveCa2+ Channel Blockers
AmlodepineAngina, Hypertension
5-10 mg once daily
intolerance to side effects: edema, constipation, hypotension
Nifedipine Angina, Hypertension 30-90 mg daily hypotension, constipation
Beta-Blockers
PropranololAngina, Hypertension 20-80 mg qid
Asthma, AV conduction block, heart failure
Clopidogrel Anti-Platelet 75 mg daily GI bleeding
Statins Hyperlipidemia 10-80 mg Liver disease
Platelet Aggregation Inhibitors
Anti-Hyperlipidemic Drugs
Reference: Harrison’s Principles of Internal Medicine, 17th EditionReference: Harrison’s Principles of Internal Medicine, 17th Edition
5959
NON-PHARMACOLOGICAL APPROACH
• risk for myocardial ischemia associated with in age• Risk: Men > Women (pre-menopausal)
• Cease smoking• Maintenance of a proper diet• Exercise regularly• Decrease alcohol consumption
60
THANK YOUTHANK YOU
MACALMA, GLENNMACAPAGAL, JUSTIN ROMEOMADRID, BIANCAMALABANAN, MICHELLEMALACA, JOSEPH CHESTERMALLARI, ROMINA GRIZELDAMALVAR, ALFREDMAMAUAG, MARY JOYMANAHAN, JOYCEMANALO, VICTORIA CAMILLEMANANSALA, PRINCESSMANCOL, MATILDE CLAIREMANDAPAT, JANICEMARANAN, REAGAN
MACALMA, GLENNMACAPAGAL, JUSTIN ROMEOMADRID, BIANCAMALABANAN, MICHELLEMALACA, JOSEPH CHESTERMALLARI, ROMINA GRIZELDAMALVAR, ALFREDMAMAUAG, MARY JOYMANAHAN, JOYCEMANALO, VICTORIA CAMILLEMANANSALA, PRINCESSMANCOL, MATILDE CLAIREMANDAPAT, JANICEMARANAN, REAGAN